Insmed Reports Q4 Loss, Meets Revenue Expectations
BRIDGEWATER, N.J. (AP) - Insmed Inc. (INSM) announced a fourth-quarter loss of $235.5 million. On a per-share basis, the company reported a loss of $1.32, falling short of Wall Street estimates. Seven analysts polled by Zacks Investment Research had forecast a loss of $1.15 per share.
Despite missing earnings expectations, Insmed exceeded revenue projections with $104.4 million, surpassing the $104.3 million predicted by five Zacks analysts. The biopharmaceutical company specializes in inhaled treatments for rare lung diseases.
For the full year, Insmed reported a loss of $913.8 million, or $5.57 per share, on revenue of $363.7 million.